HAIFA, Israel--(BUSINESS WIRE)--
Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced it has been selected as one of the Israeli innovators in the stem cell field to present at The Israeli Presidential Conference 2009: Facing Tomorrow – Tomorrow's Industries exhibition, on Oct. 20-22, at the Congress Center of the Jerusalem International Convention Center in Jerusalem, Israel. During the conference, members of Pluristem’s management team will be available to discuss the company’s innovative stem cell technology and its leading position in Israel’s biotechnology industry.
“We are a clinical stage biotechnology company with proprietary technology in the stem cell industry,” said Zami Aberman, chairman and CEO of Pluristem. “The invitation to participate in this conference for the second consecutive year is further indication of the significance of Pluristem’s human placenta derived cell therapy products.”
The Israeli Presidential Conference 2009: Facing Tomorrow is an annual global conference initiated by President Shimon Peres in 2008. The Tomorrow's Industries exhibition honors six fields of innovative technologies, including stem cells, which may shape the future of Israel and the world at large.
About Pluristem
Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.
See our product animation on YouTube: Animation, the content of which is not part of this press release.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
For more information visit our website at www.pluristem.com, the content of which is not part of this press release.
